Pfizer's Ibrance, under threat from Novartis and Lilly, leans on real-world data in breast cancer

Retrieved on: 2021-03-26 15:45:00

Tags for this article:

Click the tags to see associated articles and topics

Pfizer's Ibrance, under threat from Novartis and Lilly, leans on real-world data in breast cancer. View article details on hiswai:

Excerpt

Pfizer's Ibrance, used alongside Novartis' hormone therapy Femara, cut the risk of death by 34% in women with HR-positive, HER2-negative ...

Article found on: www.fiercepharma.com